Forest Labs News (NYSE:FRX)
| Latest Forest Labs News Headlines | | Date | Time | Source | | | 10/07/2008 | 8:00AM | PRNUS | Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Const
- Data Presented Today at ACG Annual Scientific Meeting -
ORLANDO, Fla., Oct. 7 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals, Inc. (formerly Microbia, Inc.) and Forest Laboratories, Inc. (NYSE:FRX) today announced the presentation of results from a Phase 2b study assessing linaclotide's safety and efficacy in... More...>> |
| 10/06/2008 | 11:35AM | PRNUS | Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings
NEW YORK, Oct. 6 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX), an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2009 Second Quarter financial results before the U.S. stock market opens on Tuesday, October 21, 2008. Later that day, at 10:00 AM EDT, Forest... More...>> |
| 10/01/2008 | 4:43PM | PRNUS | Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings
NEW YORK, Oct. 1 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX), an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2009 Second Quarter financial results before the U.S. stock market opens on Tuesday, October 21, 2008. Later that day, at 10:00 AM EDT, Forest... More...>> |
| 09/30/2008 | 2:00AM | PRNUS | Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Carip
NEW YORK and BUDAPEST, Hungary, Sept. 30 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX) and Gedeon Richter Plc today announced preliminary top-line results from a phase II clinical trial of cariprazine (RGH-188), an investigational antipsychotic, in patients with acute mania associated with bipolar I... More...>> |
| 09/23/2008 | 6:07PM | PRNUS | Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
- Comprehensive Phase 3 Clinical Program Initiated -
CAMBRIDGE, Mass. and NEW YORK, Sept. 23 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals (formerly Microbia) and Forest Laboratories, Inc. (NYSE:FRX) today announced they will present results of a Phase 2b study investigating linaclotide's safety and efficacy in... More...>> |
| 09/15/2008 | 8:45AM | PRNUS | Forest Laboratories, Inc. Appoints Frank Murdolo, Vice President - Investor Relations
NEW YORK, Sept. 15 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX) announced today that it has appointed Frank Murdolo, Vice President - Investor Relations.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO)
Mr. Murdolo joins Forest following eleven years with GlaxoSmithKline PLC where... More...>> |
| 09/04/2008 | 8:00AM | PRNUS | USPTO Office Action in the Reexamination of U.S. Patent No. 6,545,040
NEW YORK, Sept. 4 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX) announced today that an Office Action in the Reexamination of U.S. Patent No. 6,545,040 ("the '040 patent") was received from the U.S. Patent and Trademark Office ("USPTO") by Janssen Pharmaceutica N.V., the patent holder of the '040 patent... More...>> |
| 09/03/2008 | 2:00AM | PRNUS | Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With Chronic Obstructive
NEW YORK, Sept. 3 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX) and Laboratorios Almirall, S.A. today announced results from two global Phase III studies of aclidinium bromide, a novel long-acting inhaled anticholinergic for the treatment of patients with chronic obstructive pulmonary disease (COPD... More...>> |
| 07/30/2008 | 1:30PM | PRNUS | New Data Highlight Positive Results of Namenda(R) (memantine HCl) Once-Daily Extended-Release Formulation
- Results Presented at ICAD 2008 Highlight Significant Improvement in Cognitive Performance and Global Clinical Status in Patients with Alzheimer's Disease -
CHICAGO, July 30 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX) presented today positive Phase III data of a once-daily extended-release formulation... More...>> |
| 07/22/2008 | 8:00AM | PRNUS | Forest Laboratories, Inc. Reports Fiscal First Quarter 2009 Earnings Per Share of $0.79, Including $0.08 per Share Charge for Ag
NEW YORK, July 22 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX), an international pharmaceutical manufacturer and marketer, today announced that fully diluted earnings per share equaled $0.79 in the first quarter of fiscal 2009. Reported earnings per share include a one-time pre- tax charge of $44,100,000... More...>> |
| 06/30/2008 | 4:42PM | PRNUS | Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 First Quarter Earnings
NEW YORK, June 30 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX), an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2009 First Quarter financial results before the U.S. stock market opens on Tuesday, July 22, 2008. Later that day, at 10:00 AM EDT, Forest... More...>> |
| 06/19/2008 | 7:50AM | PRNUS | Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated S
Company's Next-Generation Cephalosporin Effective Against Difficult-to-Treat Skin Infections, Including Those with methicillin-resistant Staphylococcus aureus (MRSA)
NEW YORK, June 19 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX) today announced positive results from two globally conducted, multi-center... More...>> |
| 05/20/2008 | 6:30PM | PRNUS | Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Result
- Data being presented today at Digestive Disease Week -
CAMBRIDGE, Mass. and NEW YORK, May 20 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals, Inc. (formerly Microbia, Inc.) and Forest Laboratories, Inc. (NYSE:FRX) today announced the presentation of data from a Phase 2b randomized, double-blind, placebo-controlled... More...>> |
| 05/16/2008 | 3:54PM | PRNUS | /C O R R E C T I O N -- Forest Laboratories, Inc./
In the news release, Forest Laboratories, Inc. (NYSE: FRX) and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress, issued yesterday, May 15, by Forest Laboratories, Inc. over PR Newswire, we are advised by the company that the passcode... More...>> |
| 05/15/2008 | 1:22PM | PRNUS | Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at th
NEW YORK and BARCELONA, Spain, May 15 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX), and Laboratorios Almirall, S.A. (ALM.MC) will host a webcast to discuss aclidinium bromide clinical and pre-clinical data findings presented at the American Thoracic Society Annual Congress. The webcast, which will... More...>> |
| 05/12/2008 | 8:45AM | PRNUS | Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
NEW YORK and PARSIPPANY, N.J., May 12 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX), a U.S.-based pharmaceutical company, and Daiichi Sankyo, Inc. today announced that they have terminated their co-promotion agreement for AZOR(TM)* (amlodipine and olmesartan medoxomil), Daiichi Sankyo's fixed-dose combination... More...>> |
| 05/07/2008 | 12:00PM | PRNUS | Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents
Phase III Data Presented at American Psychiatric Association Annual Meeting
WASHINGTON, May 7 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX) announced today that study results show Lexapro (escitalopram oxalate) significantly improved symptoms of depression as compared to placebo treatment and was well... More...>> |
| 04/15/2008 | 7:50AM | PRNUS | Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter Reported EPS of $0.55 Including $0.35 Per Share Charge for Lic
COMPANY PROVIDES FY'09 EPS GUIDANCE OF APPROXIMATELY $3.10-$3.20 PER DILUTED SHARE
NEW YORK, April 15 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX), a U.S.-based pharmaceutical company, today announced that fully diluted earnings per share (EPS) for the fourth quarter of fiscal year 2008 were $0.55... More...>> |
| 04/07/2008 | 1:33PM | PRNUS | Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Fourth Quarter Earnings
NEW YORK, April 7, 2008 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX), an international manufacturer and marketer of pharmaceutical products, will release its Fiscal 2008 Fourth Quarter financial results before the U.S. stock market opens on Tuesday, April 15, 2008. Later that day, at 10:00 AM EDT... More...>> |
| 03/19/2008 | 8:12AM | PRNUS | Forest Laboratories Announces Resignation of Ivan Gergel, MD
NEW YORK, March 19 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE:FRX) today announced that Ivan Gergel, MD, Senior Vice President - Scientific Affairs and President of the Forest Research Institute has resigned his position and will leave the Company effective March 31, 2008.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO... More...>> |
|
|
|